Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
myelodysplastic syndrome (MDS)
Biotech
Syros flunks phase 3 blood cancer trial, triggering loan default
Syros saw a 23.8% complete response rate in people who received the combination, compared to 18.8% in patients who got placebo on top of azacitidine.
Nick Paul Taylor
Nov 13, 2024 10:00am
Molecular Partners tweaks AML trial over 'suboptimal exposure'
Aug 27, 2024 10:00am
New EHA data show how Gilead's $4.9B bet on CD47 imploded
Jun 14, 2024 2:03pm
Geron secures 12-2 AdComm vote in favor of blood cancer drug
Mar 15, 2024 5:00am
FDA questions benefit-risk profile of Geron's imetelstat
Mar 12, 2024 12:20pm
Roivant's Hemavant bet winds down after cutting ex-Eisai drug
Feb 13, 2024 2:01pm
